How to Ethically and Effectively Publish Clinical Trial Results in Scientific Journals

Introduction: From Data to Peer-Reviewed Impact

Publishing the results of clinical trials in peer-reviewed journals is a crucial step in the research lifecycle. It transforms raw data into publicly available evidence, informs medical decision-making, and validates the ethical commitment made to trial participants. However, publication involves more than just writing a manuscript—it requires adherence to transparency policies, ethical standards, and scientific rigor.

Today’s regulatory and editorial landscape is stricter than ever. Journals—particularly those aligned with the International Committee of Medical Journal Editors (ICMJE)—now demand prospective registration, full results disclosure, and compliance with reporting standards such as CONSORT. This tutorial explores how clinical trial sponsors and investigators can navigate the publication process successfully and ethically.

Trial Registration and ICMJE Publication Policy

As a prerequisite for publication in major medical journals, trials must be prospectively registered in a publicly accessible registry approved by the WHO ICTRP (e.g., ClinicalTrials.gov, CTRI, ISRCTN). The ICMJE mandates this to prevent selective reporting and publication bias.

Key expectations include:

• Registration before the first participant is enrolled
• Use of a WHO-compliant registry
• Inclusion of the Trial Registration Number (TRN) in the manuscript

Failure to meet these conditions may lead to automatic manuscript rejection, regardless of scientific merit.

Choosing the Right Journal for Publication

Choosing the right target journal affects not only visibility but also the peer-review timeline and acceptance chances. Consider the following criteria:

• Scope alignment: Match the journal’s audience and therapeutic area
• Impact factor and indexing: Ensure indexing in PubMed, Scopus, or Web of Science
• Open access policies: Consider funder mandates for OA publishing
• Disclosure and ethics policies: Review the journal’s stance on registration, data sharing, and conflicts of interest

Top journals like NEJM, The Lancet, BMJ, and JAMA have detailed author guidelines and expect full transparency from submission.

Manuscript Structure: Following CONSORT Guidelines

The CONSORT (Consolidated Standards of Reporting Trials) statement provides a checklist and flow diagram to guide the transparent reporting of randomized controlled trials. Common manuscript sections include:

• Abstract: Structured summary with trial ID
• Introduction: Rationale, objectives, and trial design summary
• Methods: Eligibility criteria, interventions, randomization, blinding
• Results: Participant flow, outcomes, adverse events, statistical analyses
• Discussion: Interpretation, limitations, generalizability, and ethical context

Manuscripts should be concise, evidence-based, and reference all pre-registered outcomes and deviations.

Handling Negative or Inconclusive Results

One of the biggest ethical lapses in trial transparency is failure to publish negative or inconclusive results. However, many journals explicitly encourage such submissions because they:

• Prevent unnecessary duplication of research
• Reduce publication bias
• Support accurate systematic reviews and meta-analyses

Authors should resist the urge to suppress disappointing findings. Instead, contextualize them in the discussion section and focus on scientific learning and future implications.

Addressing Authorship and Conflict of Interest

Authorship must reflect substantial contribution to the conception, design, data analysis, or manuscript drafting. Most journals follow ICMJE authorship criteria:

• Contribution to trial design or data collection
• Drafting or revising the manuscript
• Approval of the final version
• Accountability for content accuracy

Disclosures of financial or personal conflicts of interest are mandatory. Failure to do so can lead to retraction or reputational harm.

Preprint Servers and Early Data Sharing

Increasingly, trial results are shared via preprint servers such as medRxiv or bioRxiv. While these are not peer-reviewed, they allow early access to findings and support open science. However:

• Journals may have policies regarding prior dissemination—always check
• Clearly label the version as a preprint in the manuscript submission
• Avoid media press releases until after peer-review, unless permitted

Preprints are useful for public health emergencies (e.g., COVID-19) or when rapid dissemination is critical.

Best Practices for a Successful Submission

To maximize publication success:

• Include the trial registration number in the title page and abstract
• Cross-check outcomes with registered protocol—explain deviations
• Use reporting checklists (e.g., CONSORT, SPIRIT, STROBE)
• Submit to a journal with a history of publishing similar trials
• Ensure all disclosures and acknowledgments are included

Consider submitting graphical abstracts, plain language summaries, and data availability statements to improve transparency and reach.

Conclusion: Publishing Is a Transparency Milestone

Publishing clinical trial results in peer-reviewed journals is both a scientific obligation and a regulatory requirement. With expectations rising around transparency, ethical authorship, and data accessibility, sponsors must treat publication planning as a core component of trial design.

By following registry policies, reporting standards, and journal requirements, researchers can ensure their findings contribute to the evidence base, respect participant contributions, and stand up to public and scientific scrutiny.

Meeting U.S. Regulatory Requirements for Clinical Trial Results Disclosure

Introduction: The Importance of Posting Results

Results disclosure is a fundamental component of clinical trial transparency in the United States. While trial registration alerts the public to a study’s existence, posting trial results ensures that the findings—positive or negative—are available for patients, researchers, regulators, and healthcare professionals.

Under FDAAA 801 and the Final Rule (42 CFR Part 11), sponsors and responsible parties must post summary results for applicable clinical trials (ACTs) on ClinicalTrials.gov. Failure to comply can result in legal penalties, public notices of noncompliance, and loss of funding from government agencies like the NIH.

Who Must Report and What Is an Applicable Clinical Trial?

The obligation to disclose results falls on the “responsible party,” usually the trial sponsor or designated principal investigator. This includes:

• Drug, biologic, or device manufacturers sponsoring the study
• Academic institutions leading investigator-initiated trials
• Collaborative groups or consortia listed as sponsors or responsible parties

An Applicable Clinical Trial (ACT) is defined as a controlled clinical study (excluding most Phase I drug trials and small feasibility device studies) involving FDA-regulated products that are not exempt from IND or IDE requirements.

When Must Results Be Submitted?

Results for ACTs must be submitted within 12 months after the “Primary Completion Date”, which is the date when the final subject was examined or received an intervention for the purpose of final collection of data for the primary outcome measure.

In rare cases, responsible parties may request a delay or certification extension—for example, when FDA approval is pending—but these requests are time-bound and must be justified with supporting documentation.

What Must Be Included in Results Submissions?

ClinicalTrials.gov requires a structured and standardized results summary. The following modules must be completed:

• Participant Flow: Number of participants at each trial stage and reasons for dropout
• Baseline Characteristics: Demographics and baseline measures by arm/group
• Outcome Measures: Results for each pre-specified primary and secondary endpoint, including units and statistical analyses
• Adverse Events: Serious and other adverse events categorized by frequency and severity

All information must be entered into structured tables using ClinicalTrials.gov’s web-based submission system or through XML uploads via the Protocol Registration and Results System (PRS).

Adverse Events: Reporting Expectations

Reporting of adverse events is mandatory and includes two main tables:

1. Serious Adverse Events: Events that resulted in death, were life-threatening, required hospitalization, caused disability, or led to birth defects
2. Other (Non-Serious) Adverse Events: Events occurring at or above 5% frequency in any arm/group

Events must be categorized using MedDRA system organ class and preferred terms. If no events occurred, the table must still be submitted with a “0” entry to comply with formatting rules.

Quality Control and Posting Timeline

After submission, ClinicalTrials.gov conducts a Quality Control (QC) review, which typically takes 30–45 days. Sponsors will receive feedback and may need to revise and resubmit data if inconsistencies or missing fields are identified.

Once passed, the data is posted publicly and becomes searchable by the public. As of 2024, ClinicalTrials.gov lists the date results are submitted, posted, and revised, maintaining transparency of sponsor responsiveness.

Case Example: NIH-Funded Trial on Asthma

A multicenter trial funded by the NIH on asthma drug efficacy completed data collection in July 2023. The sponsor submitted results by July 2024 but failed initial QC due to incomplete outcome measure details.

After revision, results were posted in October 2024. Despite the delay, the sponsor avoided penalties by initiating submission on time and responding to QC comments promptly—highlighting the importance of early and complete submission.

Penalties for Late or Incomplete Reporting

The FDA has legal authority to enforce compliance with FDAAA 801. Penalties may include:

• Monetary fines up to $13,237 per day of noncompliance
• Public notices of violation listed on the FDA’s enforcement page
• Loss of eligibility for federal research grants
• Institutional damage to reputation and future partnerships

In 2021, the FDA issued over a dozen noncompliance notices, including to major universities and large CROs. Public enforcement has increased visibility into result posting performance.

Formatting and Common Pitfalls

Common issues that delay posting include:

• Inconsistent unit definitions across arms
• Failure to provide statistical analysis plans or p-values
• Missing denominators in AE tables
• Inadequate explanation of outcome time points

To avoid rejection, sponsors should prepare a results submission plan that mirrors the original protocol endpoints and statistical analysis methods, aligning submitted data with registered outcomes.

Best Practices for Results Disclosure Compliance

• Create a disclosure calendar aligned with your trial milestones
• Start results preparation before trial closeout using draft tables
• Assign roles to trained medical writers or disclosure leads
• Use validation tools provided by PRS to check format before submission
• Maintain internal QC reviews to catch issues prior to external QC

Larger organizations often implement SOPs and templates to streamline submissions and avoid inconsistencies across trial teams.

Conclusion: Transparency Begins with Results

Posting results on ClinicalTrials.gov is not a bureaucratic formality—it’s a legal, ethical, and scientific obligation. With increasing scrutiny from regulators, funders, and the public, trial sponsors must prioritize accuracy, timeliness, and completeness of their results submissions.

By understanding the FDAAA 801 requirements and building internal compliance structures, sponsors can not only avoid penalties but also contribute meaningfully to scientific progress and public trust in medical research.